Thursday, December 8, 2022

Anaqua, PatSnap to deliver end-to-end pharma IP management solution

KUALA LUMPUR, Dec 8 (Bernama) -- Anaqua Inc, a United States-based leading provider of innovation and intellectual property (IP) management technology, is partnering with innovation intelligence platform, PatSnap.

In a statement, the company said the collaboration will deliver an enhanced IP management solution to provide Anaqua’s pharmaceutical industry clients with a more detailed and informed view of the market and competitive landscape for key use cases.

The combined Anaqua AQX Pharma and PatSnap Synapse solutions will help AQX Pharma clients further enhance competitiveness, keep up with the fast-paced requirements of the current market, and eliminate duplicated work across functions, among others.

“AQX Pharma helps clients manage the business aspects of pharmaceutical IP management, while Synapse powers the external aspects of drug discovery through external and competitor drug discovery processes.

“We are pleased to offer a complete pharma innovation solution, which can be further complemented by leveraging Anaqua’s strategic integrations, such as its innovation management solution, ideaPoint,” said Anaqua’s senior vice-president of Product and Innovation, Vincent Brault.

PatSnap’s Synapse solution will give AQX Pharma users access to millions of data points, utilising best-in-class algorithms and expert manual curation, thus providing them with a comprehensive 360-degree market view and adding strategic value to drug development processes and strategy.

The new integration is in response to clients’ requests to access more pharmaceutical market data within the AQX platform to improve internal team efficiency and streamline processes.

The integration will support the sharing of deeper intelligence between clients and partners, and simplify administration processes through features such as docket personalisation that will allow teams to focus on their most strategic initiatives.

-- BERNAMA




No comments:

Post a Comment